This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Nomura Adjusts Shenzhen New Industries Biomedical Engineering’s Price Target to 93.36 Yuan From 98.15 Yuan, Keeps at Buy MT
Shenzhen New Industries Biomedical Engineering Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Shenzhen New Industries Biomedical Engineering Gets Nod to Register Five Devices MT
Shenzhen New Industries Biomedical Engineering's 2023 Profit Jumps 25% MT
Shenzhen New Industries Biomedical Engineering Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Nomura Adjusts New Industries Biomedical Engineering’s Price Target to 98.15 Yuan From 86.13 Yuan, Keeps at Buy MT
Nomura Adjusts Shenzhen New Industries Biomedical Engineering's Price Target to 86.13 Yuan From 75.19 Yuan, Keeps at Buy MT
Shenzhen New Industries Biomedical Engineering Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
Nomura Adjusts Shenzhen New Industries Biomedical Engineering's Price Target to 75.19 Yuan From 71.58 Yuan, Keeps at Buy MT
Shenzhen New Industries' Profit Jumps 32% in H1 MT
Shenzhen New Industries Biomedical Engineering Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Nomura Adjusts Shenzhen New Industries Biomedical Engineering’s Price Target to 71.58 Yuan From 69.88 Yuan, Keeps at Buy MT
Shenzhen New Industries Biomedical Engineering Co., Ltd. Announces Final Profit Distribution Plan to Be Implemented on A Shares for the Year 2022, Payable on 08 June 2023 CI
Shenzhen New Industries Biomedical Engineering's Shareholders Plan To Unload Company Stakes CI
Certain A Shares of Shenzhen New Industries Biomedical Engineering Co., Ltd. are subject to a Lock-Up Agreement Ending on 12-MAY-2023. CI
Nomura Adjusts New Industries Biomedical's Price Target to 69.88 Yuan From 71.05 Yuan, Keeps at Buy MT
Shenzhen New Industries Biomedical Engineering Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Shenzhen New Industries Biomedical Engineering Co., Ltd. Announces Profit Distribution Proposal for 2022 CI
Shenzhen New Industries Biomedical Engineering Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Nomura Adjusts Shenzhen New Industries Biomedical Engineering’s Price Target to 71.05 Yuan From 67.87 Yuan, Keeps at Buy MT
Shenzhen Yinghe Brain Science Co., Ltd announced that it has received $14.800000 million in funding from Eli Lilly Investment Consulting Shanghai Co., Ltd., Shenzhen New Industries Biomedical Engineering Co., Ltd., Beijing Enlight Media Co., Ltd., Xi'an Xijiao 1896 Capital Management Co., Ltd., Shenzhen Qianhai BangQin Investment Co., Ltd. and other investors. CI
Shenzhen New Industries Receives Provincial Registration Certificate for Parathyroid Hormone Kit MT
Shenzhen New Industries Biomedical Engineering Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022 CI
Shenzhen New Industries Biomedical Engineering Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022 CI
Shenzhen New Industries Biomedical Engineering Co., Ltd. Implements Final Cash Dividend for 2021, Payable on 23 June 2022 CI
Chart Shenzhen New Industries Biomedical Engineering Co., Ltd.
More charts
Shenzhen New Industries Biomedical Engineering Co Ltd is a company engaged in research and development, production and sales of in-vitro diagnostics instruments and supporting reagents. The Company operates three segments, including Instruments and Supporting Software, Reagents, Accessories and Others. Instruments and Supporting Software segment is involved in the production and sales of MAGLUMI automatic chemiluminescence immunoassay analyzer series products and Biossays automatic biochemical analyzer series products. Reagents segment operates the sales of supporting reagents for the analyzers. The products are applied in the examination of Gonads, thyroid gland, glucose metabolism, kidney function and so on. Accessories and Others segment is responsible for the manufacturing and sales of accessories related to in-vitro diagnostics equipment. The Company sells its products both in domestic and international markets, including Asia, Europe, America and Africa.
More about the company
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
13
Last Close Price
75.13 CNY
Average target price
84.5 CNY
Spread / Average Target
+12.47%
Consensus
  1. Stock Market
  2. Equities
  3. 300832 Stock
  4. News Shenzhen New Industries Biomedical Engineering Co., Ltd.
  5. Nomura Adjusts Shenzhen New Industries Biomedical Engineering's Price Target to 86.13 Yuan From 75.19 Yuan, Keeps at Buy
-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.
BENEFIT NOW